⌘K
t
Arecor Therapeutics plc announced that on 5 December 2022, it granted a total of 270,000 options under its Long Term Incentive Plan to Senior Management (PDMRs). These LTIP Options have an exercise price of 1p and were granted to individuals including Sarah Howell (80,000 options), Shafiq Choudhary (50,000 options), Jane Jezek (40,000 options), Susan Lowther (63,333 options), David Gerring (20,000 options), and Fiona Lawrence (16,667 options).
| Date | 6 Dec 2022 |
| Time | 16:03:14 |
| Category | Director/PDMR dealings |
| ID | 8052I |
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of LTIP Options and PDMR Dealing
Cambridge, UK, 6 December 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that on 5 December 2022, it granted a total of 270,000 options under the Company's Long Term Incentive Plan ("LTIP Options") over new ordinary shares of 1p each in the Company ("Ordinary Shares").
The LTIP Options have an exercise price of 1p and are granted to Senior Management (persons discharging managerial responsibilities ("PDMRs") of the Company. Performance conditions include commercial objectives and Total Shareholder Return during the three-year performance period.
The LTIP Options are subject to continued service and the extent to which the performance conditions are satisfied. Vested LTIP Options will normally be exercisable until the tenth anniversary of the grant date, after which time they will lapse. They are subject to a condition that the LTIP Options or the Ordinary Shares acquired on exercise of the LTIP Options (other than those sold to cover tax and National Insurance) are held for a minimum one-year period from vesting.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
For further information, please contact:
|
Arecor Therapeutics plc
|
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected]
|
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected]
|
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: [email protected] |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Angela Gray |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Shafiq Choudhary |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Managing Director, Tetris Pharma Ltd |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
50,000 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
David Gerring |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
VP Development |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
20,000 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Sarah Howell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Chief Executive Officer |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
80,000 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Jane Jezek |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Chief Scientific Officer |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
40,000 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Fiona Lawrence |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
VP Clinical & Regulatory Affairs and QA |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
16,667 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
|
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name: |
Susan Lowther |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status: |
Chief Financial Officer |
||||
|
b) |
Initial notification/Amendment: |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name: |
Arecor Therapeutics plc |
||||
|
b) |
LEI: |
98450093D12I3A8DDD58 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument: Identification code: |
Ordinary shares of 1 pence each GB00BMWLM973 |
||||
|
b) |
Nature of the transaction: |
Grant of options over ordinary shares |
||||
|
c) |
Price(s) and volume(s): |
|
||||
|
d) |
Aggregated information: · Aggregated volume: · Price: |
63,333 N/A |
||||
|
e) |
Date of the transaction: |
5 December 2022 |
||||
|
f) |
Place of the transaction: |
Outside of a trading venue |
||||